COLLEGIUM PHARMACEUTICAL INC (COLL) Stock News
NASDAQ:COLL - Nasdaq - US19459J1043 - Common Stock - Currency: USD
COLL Latest News, Press Relases and Analysis
Collegium to Participate in Upcoming Investor Conferences
STOUGHTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in...
Collegium to Participate in Upcoming Investor Conferences
Collegium Pharmaceutical’s (NASDAQ:COLL) Q4 Sales Top Estimates, Stock Jumps 14.1%
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 21.5% year on year to $181.9 million. The company expects the full year’s revenue to be around $742.5 million, close to analysts’ estimates. Its non-GAAP profit of $1.77 per share was 15.1% above analysts’ consensus estimates.
Collegium Pharmaceutical’s (NASDAQ:COLL) Q4 Sales Top Estimates, Stock Jumps 14.1%
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 21.5% year on year to $181.9 million. The company expects the full year’s revenue to be around $742.5 million, close to analysts’ estimates. Its non-GAAP profit of $1.77 per share was 15.1% above analysts’ consensus estimates.
Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results
– Generated Record Quarterly and Full-Year Net Revenue of $181.9 Million and $631.4 Million – – Reported Quarterly Jornay PM® Net Revenue of $29.3...
Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results
Collegium Pharmaceutical (COLL) Reports Earnings Tomorrow: What To Expect
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting earnings tomorrow after the bell. Here’s what to look for.
Collegium Pharmaceutical (COLL) Reports Earnings Tomorrow: What To Expect
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting earnings tomorrow after the bell. Here’s what to look for.
Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025
STOUGHTON, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report fourth quarter and...
Dr. Reddy's Stock Hit All-Time High Last Month. Ready To Climb Again?
Dr. Reddy's Labs sees its Relative Strength Rating enter the 80-plus level.
Mentions: RDY
Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025
Collegium Appoints Nancy S. Lurker to its Board of Directors
Collegium Provides 2025 Financial Guidance and Business Update
– Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM® Net Revenue Expected to be in Excess of $135 Million – –...
Collegium Provides 2025 Financial Guidance and Business Update
Collegium to Participate in Upcoming Investor Conferences
Collegium Reports Record Third Quarter 2024 Financial Results
– Generated Record Q3’24 Net Revenue of $159.3 Million, Up 17% Year-over-Year, Driven by Record Belbuca® Revenue of $53.2 Million and Record Xtampza® ER...
Collegium Reports Record Third Quarter 2024 Financial Results
Collegium Appoints Vikram Karnani as Chief Executive Officer
Vikram Karnani is a Proven Industry Leader with Extensive Experience Growing Commercial Biopharmaceutical Businesses...
Collegium Appoints Vikram Karnani as Chief Executive Officer
Vikram Karnani is a Proven Industry Leader with Extensive Experience Growing Commercial Biopharmaceutical Businesses
Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024
Collegium Completes Acquisition of Ironshore Therapeutics
– Adds Commercial Product Jornay PM®, Establishing Collegium’s Presence in Neurology (ADHD) – – Collegium Updates 2024 Financial Guidance to Reflect...
Collegium Completes Acquisition of Ironshore Therapeutics
Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference
STOUGHTON, Mass., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical...
Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference
Collegium Announces Eight Poster Presentations at PAINWeek Conference 2024
Organon Stock Sees Relative Strength Rating Rise To 91
On Tuesday, Organon[ stock hit an key technical milestone, seeing its Relative Strength Rating jump to 91, up from 88 the day before.
Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold
On Tuesday, generic drug maker Organon stock had its Relative Strength (RS) Rating upgraded to 83, up from 78 a day earlier.
COLL Stock Earnings: Collegium Pharmaceutical Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Collegium Pharmaceutical (NASDAQ:COLL) just reported results for the second qua...
COLL Stock Earnings: Collegium Pharmaceutical Beats EPS, Beats Revenue for Q2 2024
COLL stock results show that Collegium Pharmaceutical beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Collegium Reports Second Quarter 2024 Financial Results
– Generated Q2’24 Net Revenue of $145.3 Million and Record Belbuca® Revenue of $52.2 Million, Up 7% and 21% Year-over-Year, Respectively – –...